Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Immuneering Corporation stock (Immuneering Corporation)

Buy Immuneering Corporation stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Immuneering Corporation is a biotechnology business based in the US. Immuneering Corporation shares (IMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.86 – a decrease of 7.46% over the previous week. Immuneering Corporation employs 66 staff and has a trailing 12-month revenue of around $455.

Our top picks for where to buy Immuneering stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Immuneering Corporation stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – IMRX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Immuneering Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Immuneering Corporation stock price (NASDAQ: IMRX)

Use our graph to track the performance of IMRX stocks over time.

Immuneering Corporation shares at a glance

Information last updated 2024-11-01.
Latest market close$1.86
52-week range$1.00 - $8.89
50-day moving average $2.01
200-day moving average $2.59
Wall St. target price$11.21
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-1.90

Is it a good time to buy Immuneering Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immuneering Corporation price performance over time

Historical closes compared with the close of $1.92 from 2024-10-30

1 week (2024-10-25) -4.48%
1 month (2024-10-01) -17.24%
3 months (2024-08-01) 42.22%
6 months (2024-05-01) 25.49%
1 year (2023-11-01) -70.37%
2 years (2022-11-01) -86.24%
3 years (2021-11-01) 26.84
5 years (2019-10-28) N/A

Immuneering Corporation financials

Revenue TTM $455
Gross profit TTM $158,830
Return on assets TTM -37.42%
Return on equity TTM -61.81%
Profit margin 0%
Book value $2.24
Market Capitalization $56.9 million

TTM: trailing 12 months

Immuneering Corporation share dividends

We're not expecting Immuneering Corporation to pay a dividend over the next 12 months.

You may also wish to consider:

Immuneering Corporation share price volatility

Over the last 12 months, Immuneering Corporation's shares have ranged in value from as little as $1 up to $8.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immuneering Corporation's is -0.453. This would suggest that Immuneering Corporation's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Immuneering Corporation has bucked the trend.

To put Immuneering Corporation's beta into context you can compare it against those of similar companies.

Immuneering Corporation overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. .

Frequently asked questions

null
What percentage of Immuneering Corporation is owned by insiders or institutions?
Currently 29.124% of Immuneering Corporation shares are held by insiders and 32.462% by institutions.
How many people work for Immuneering Corporation?
Latest data suggests 66 work at Immuneering Corporation.
When does the fiscal year end for Immuneering Corporation?
Immuneering Corporation's fiscal year ends in December.
Where is Immuneering Corporation based?
Immuneering Corporation's address is: 245 Main Street, Cambridge, MA, United States, 02142
What is Immuneering Corporation's ISIN number?
Immuneering Corporation's international securities identification number is: US45254E1073

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site